TREND OF USE OF DIFFERENT ANTIMIGRAINE MEDICATIONS AND AWARENESS OF MIGRAINE, SURVEY BASED STUDY IN JALANDHAR
Â Objective: A brain disease, migraine is a special type of headache that causes highly intense, throbbing quality pain in half head or any one side of the head. It may be due to several reasons such as food intake, sleep disturbance, and stress or tension. Hormonal disturbance can result in migraine. There is no specific treatment for migraine. Analgesics or pain killers may prove effective in migraine. To prevent it cautions must be taken. Our study aims to find out the awareness and prevalence of migraine among students of different schools, colleges, universities, and professional institutes of Jalandhar city. Further, the drug consumption pattern of most prominent used antimigraine medications was also calculated.
Method: The crossâ€“sectional data were collected through a questionnaire from the random sample in the month from August 2016 to November 2016 in Jalandhar. To check the drug consumption, daily defined dose (DDDs) or drug usage has been calculated using the DDD recommended by the World Health Organization.
Results: According to our survey, 80% candidates have heard about the term migraine.'' 36% candidates are aware about the causes, 58% aware about the signs and symptoms of migraine while 23% candidates are aware about the treatment. The overall awareness rate of migraine in candidates is about 45%.
Conclusion: The prevalence of migraine is more in women than men by a factor of about 3:1. Triptans are mostly found to be effective for the treatment of migraine. The main cause of migraine was found to be stress or tension and the common symptom of migraine was throbbing or pulsating pain on one side of the head.
2. Naveed S, Hameed A, Sharif N. Awareness and prevalence of migraine, survey based study in Karachi. Int J Biol Sci Appl 2014;1(4):157-61.
3. Cady RK, Farmer K. Acute and preventative treatment of episodic migraine. In: Diamond S, Cady RK, Diamond ML, Martin VT, editors. Headache and Migraine Biology and Management. 1st ed. USA: Academic Press; 2015. p. 69.
4. Steiner TJ, Stovner LJ, Birbeck GL. Migraine: The seventh disabler. J Headache Pain 2013;14(1):1.
5. World Health Organization. Headache Disorders;2016 Available from: http://www.who.int/mediacentre/factsheets/fs277/en. [Last cited on 2017 Jun 12].
6. University of Maryland Medical Center. Migraine Headaches;2016 Available from: http://www.umm.edu/health/medical/reports/articles/ migraine-headaches. [Last cited on 2017 Jun 12].
7. Hurney C, Faulkner D. Migraine headaches. In: Ballington DA, Laughlin MM, editors. Pharmacology for Technicians. India: New Age International Publishers; 2005. p. 133-4.
8. Migraine Again. The Best Migraine Cities in the US (and the Worst);2016 Available from: http://www.migraineagain.com/the-best-migraine-cities-in-the-us-and-the-worst. [Last cited on 2017 Jun 12].
9. Migraine Research Foundation. Migraine Facts;2016 Available from: https://www.migraineresearchfoundation.org/about-migraine/ migraine-facts. [Last cited on 2017 Jun 12].
10. Girotra P, Singh SK, Saini D. Disentangling the intricacies of migraine: A review. CNS Neurol Disord Drug Targets 2014;13(5):776-91.
11. Mayo Clinic. Symptoms and Causes;2016 Available from: http://www. mayoclinic.org/diseases-conditions/migraine-headache/symptoms-causes/dxc-20202434. [Last cited on 2017 Jun 12].
12. Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC, et al. Chronic migraine prevalence, disability, and sociodemographic factors: Results from the American Migraine Prevalence and Prevention Study. Headache 2012;52(10):1456-70.
13. Medline Plus. Migraine;2016 Available from: https://www.medlineplus. gov/ency/article/000709.htm. [Last cited on 2017 Jun 12].
14. Goadsby PJ. Migraine: Diagnosis and management. Intern Med J 2003;33(9-10):436-42.
15. Horne T, Smillie L. Migraine. In: Bennett PN, Brown MJ, editors. Clinical Pharmacology. 9th ed. Spain: Churchill Livingstone; 2003. p. 326-8.
16. Kelman L. Review of frovatriptan in the treatment of migraine. Neuropsychiatr Dis Treat 2008;4(1):49-54.
17. Hyde M, Mortimer A, Lowson K. Migraine and antimigraine drugs. In: Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G, editors. Rang and Daleâ€™s Pharmacology. 9th ed. Spain: Churchill Livingstone; 2012. p. 199-202.
18. Tepper SJ, Spears RC. Acute treatment of migraine. Neurol Clin 2009;27(2):417-27.
19. WHO Collaborating Centre for Drug Statistics Methodology. Definition and General Considerations;2016 Available from: http://www.whocc. no/ddd/definition _and_general_considera. [Last cited on 2017 Jun 12].
20. Ghanname I, Ahid S, Berrada G, Belaiche A, Hassar M, Cherrah Y. Trends in the use of antiasthmatic medications in Morocco (1999- 2010). Springerplus 2013;2(1):82.
21. WHO Collaborating Centre for Drug Statistics Methodology. ATC/ DDD Index 2016;2016 Available from: http://www.whocc.no/atc_ddd_ index. [Last cited on 2017 Jun 12].
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.